

CONTENTS

Preface, xi

Acknowledgements, xiii

User guide, xiv

1 · THE BASIS OF IMMUNOLOGY I — Innate Immunity

Barriers against infection, 2

Phagocytic cells kill micro-organisms, 2

 'Professional' phagocytes, 2

 Phagocytosis, 4

 Killing, 4

Complement facilitates phagocytosis, 7

 Complement and its activation, 7

 Complement has a range of biological functions, 8

The complement-mediated acute inflammatory reaction, 10

Humoral mechanisms provide a second defensive strategy,
11

 Acute phase proteins, 11

 Interferons, 12

Extracellular killing, 13

 Natural killer (NK) cells, 13

 Eosinophils, 13

2 · THE BASIS OF IMMUNOLOGY II — Specific Acquired Immunity

The need for specific immune mechanisms, 15

Antibody — the specific adaptor, 15

 Antibody initiates a new complement pathway
 ('classical'), 15

 Complexed antibody activates phagocytic cells, 16

The cellular basis of antibody production, 17

 Antibodies are made by lymphocytes, 17

 Antigen selects the lymphocytes which make antibody,
 19

 The need for clonal expansion means humoral immunity
 must be acquired, 21

Acquired memory, 21

 Secondary antibody responses, 22

The specificity of acquired immunity, 22

Vaccination, 24

Cell-mediated immunity protects against intracellular
organisms, 25

 Lymphokine-producing T-cells help macrophages to kill
 intracellular parasites, 25

 Killing of virally infected cells by cytotoxic T-cells, 25

Immunopathology, 27

Summary, 27

Further reading, 29

3 · MOLECULES WHICH RECOGNIZE ANTIGEN

The immunoglobulins, 31

The basic structure is a four-peptide unit, 31

Amino acid sequences reveal variations in immunoglobulin
structure, 32

 Isotypes, 33

 Allotypes, 34

 Idiotypes, 36

Immunoglobulins are folded into globular domains which
subserve different functions, 36

 Immunoglobulin domains have a characteristic
 structure, 36

 The variable domain binds antigen, 38

 Constant region domains determine secondary biological
 function, 38

- Immunoglobulin classes and subclasses, 40
 - Immunoglobulin G, 40
 - Immunoglobulin A, 40
 - Immunoglobulin M, 41
 - Immunoglobulin D, 43
 - Immunoglobulin E, 43
 - Immunoglobulin subclasses, 43
- The major histocompatibility complex (MHC), 43**
- Class I and class II molecules are membrane-bound heterodimers, 43
- Gene map of the major histocompatibility complex, 44
- The genes of the MHC display remarkable polymorphism, 44
 - Nomenclature, 46
- Inheritance of the MHC, 47
- The tissue distribution of MHC molecules, 47
- MHC functions, 47
- The T-cell receptor, 48**
- The generation of diversity for antigen recognition, 49**
- Multiple gene segments code for antibody, 49
- A similar pattern of genes codes for the T-cell receptor, 50
- The mechanisms which generate tremendous diversity from limited gene pools, 50
 - Intrachain amplification of diversity, 50
 - Interchain amplification, 52
 - Somatic hypermutation, 52
- Summary, 53**
- Further reading, 54

vi

4 · THE RECOGNITION OF ANTIGEN

I — Primary Interaction

- What is an antigen?, 55
- Of epitopes and antigen determinants, 55
- Antigens and antibodies interact by spatial complementarity not by covalent bonding, 56
- The forces binding antigen to antibody become large as intermolecular distances become small, 58
- The affinity or strength of binding of antigen and antibody, 60
- The avidity of antiserum for antigen — the bonus effect of multivalency, 61
- The specificity of antigen recognition by antibody is not absolute, 63
- What the T-cell sees, 64
 - Haplotype restriction reveals the need for MHC participation, 64
 - Do T-cells see 'processed' antigen?, 64
 - Does specificity imply dual T-cell receptors?, 66
 - Do MHC and nominal antigen interact positively to form a complex?, 66
- Features associated with antigenicity, 67
- Summary, 68**
- Further reading, 68

5 · THE RECOGNITION OF ANTIGEN

II — Detection and Application

- Precipitation, 69
 - The classical precipitation reaction, 69

- Visualization of the precipitation reaction in gels, 69
- Indirect precipitation of complexes, 73
- Agglutination by antibody, 74
- Purification of antigens and antibodies by affinity chromatography, 76
- Immunoassay of antigen and antibody with labelled reagents, 76
 - A wide variety of labels is available, 76
 - Soluble phase immunoassays, 76
 - Solid phase immunoassays, 76
- Immunoblotting (Western blots), 78
- Immunohistochemistry — localization of antigens in cells and tissues, 79
 - Immunofluorescence, 79
 - Reaction with cell surface antigens, 80
 - Other labelled antibody methods, 81
- Cell separation techniques, 81
- Neutralization of biological activity, 83
- Summary, 84**
- Further reading, 84

6 · THE ACQUIRED IMMUNE RESPONSE

I — Consequences of Antigen Recognition

- Where does it all happen? — The anatomy of the immune response, 85**
- Lymph node, 85
 - B-cell areas, 86
 - T-cell areas, 86
 - Lymphocyte traffic, 87
- Spleen, 87
- Mucosal-associated lymphoid tissue, 87
- Bone marrow can be a major site of antibody synthesis, 87
- Where does antigen go?, 88
- The activation of T-cells, 92**
- The surface markers of immunocompetent T- and B-lymphocytes, 92
- The activation of T-cells requires two signals, 94
- The activation of B-cells, 94**
- B-cells respond to three different types of antigen, 94
 1. Type 1 thymus-independent antigens, 94
 2. Type 2 thymus-independent antigens, 95
 3. Thymus-dependent antigens — the need for collaboration with T-helper cells, 95
- The nature of B-cell activation, 96
- Clonal expansion is achieved by T-cell soluble factors, 98
- Further T-cell factors bring about maturation of effector cells, 98
- Summary, 99**
- Further reading, 100

7 · THE ACQUIRED IMMUNE RESPONSE

II — Production of Effectors

- The synthesis of humoral antibody, 101**
- Detection and enumeration of antibody-forming cells, 101

- Immunofluorescence, 101
- Plaque techniques, 101
- Protein synthesis, 101
- Class switching occurs in individual B-cells, 102
- Is the specificity of antibody secreted by the progeny the same as that of the surface immunoglobulin of the clonal parent?, 103
 - The one-cell one-antibody idea does seem O.K., 104
 - The surface antibody does appear to be related to the specificity of the secreted immunoglobulin, 106
 - Class-switched B-cells are subject to high mutation rates after the initial response, 106
- Antibody affinity, 106
 - The effect of antigen dose, 106
 - Maturation of affinity, 107
- The monoclonal antibody revolution, 107
- Cell-mediated immunity has two arms, 110**
- T-helper cells produce soluble mediators (lymphokines), 110
 - Activation, 110
 - Do different T-cell subsets make different lymphokines?, 111
 - Growth and differentiation factors, 111
 - Macrophage-related lymphokines, 112
 - The cytotoxic lymphokine, 112
- Killer T-cells, 113
 - The lethal process, 113
- Summary, 113**
- Further reading, 115

8 · THE ACQUIRED IMMUNE RESPONSE III — Control

- Antigen is a major factor in control, 116
- Antibody exerts feedback control, 116
- T-cell regulation, 117
 - T-helper cells, 117
 - T-suppressor cells, 117
 - Effector T-Cells are guided to the appropriate target by MHC surface molecules, 120
- Idiotypic networks, 120
 - Jerne's network hypothesis, 120
 - Evidence for idiotypic networks, 121
 - Regulation by idiotypic interactions, 122
 - Manipulation of the immune response through idiotypes, 124
- The influence of genetic factors, 125
 - Some genes affect general responsiveness, 125
 - Immune response linked to immunoglobulin genes, 125
 - The immune response can be influenced by the major histocompatibility complex, 126
- Are there regulatory immuno-neuroendocrine networks?, 127
- Immunological tolerance avoids self-reactivity, 129
 - Events in the neonatal period, 129
 - Events in the adult, 130
 - Mechanism of tolerance induction, 131
- Summary, 133**
- Further reading, 133

9 · THE ACQUIRED IMMUNE RESPONSE IV — Development

- Development of the immune system in early life, 134**
- The multipotential haemopoietic stem cell, 134
- The thymus provides the environment for T-cell differentiation, 134
- The differentiation of T-cells within the thymus, 136
 - Differentiation is accompanied by changes in surface markers, 136
 - Receptor rearrangement, 136
 - The imprinting of MHC restriction, 137
 - Induction of self-tolerance, 137
- B-cells differentiate in the fetal liver and then in bone marrow, 138
- Phenotypic changes in differentiating B-cells, 138
- The sequence of immunoglobulin gene rearrangements, 139
 - Allelic exclusion, 139
 - Different specific responses can appear sequentially, 140
- B-cells change in responsiveness to negative signals with age, 140
- The idiotype network in early life, 141
- The overall response in the neonate, 142
- Unregulated development gives rise to lymphoproliferative disorders, 142**
- Deregulation of the c-myc proto-oncogene is a characteristic feature of many B-cell tumours, 142
- Chromosome translocations are common in lymphoproliferative disorders, 143
- Different lymphoid malignancies show maturation arrest at characteristic stages in differentiation, 143
- Immunohistological diagnosis of lymphoid neoplasias, 144
 - Leukaemias, 144
 - Lymphomas, 144
- Plasma cell dyscrasias, 145
 - Multiple myeloma, 145
 - Waldenstrom's macroglobulinaemia, 148
 - Heavy chain disease, 148
- Immunodeficiency secondary to lymphoproliferative disorders, 148
- The evolution of the immune response, 149**
- Recognition of self is fundamental for multicellular organisms, 149
- Invertebrates have humoral defence mechanisms, 149
- B- and T-cell responses are well defined in the vertebrates, 149
- The evolution of distinct B- and T-cell lineages was accompanied by the development of separate sites for differentiation, 150
- The immunoglobulin gene superfamily of recognition molecules, 151
- Summary, 151**
- Further reading, 153

10 · IMMUNITY TO INFECTION I — Adversarial strategies

- Bacteria susceptible to killing by phagocytosis, 154**

- Bacterial strategies to avoid phagocytosis, 154
- The host counter-attack, 154
 - Toxin neutralization, 154
 - Oponsonization of bacteria, 155
 - The secretory immune system protects the external mucosal surfaces, 156
- Some specific examples, 156
- Bacteria which grow in an intracellular habitat, 158**
- Bacterial gambits, 158
- Defence is by cell-mediated immunity (CMI), 158
- Activated macrophages kill intracellular parasites, 160
- Immunity to viral infection, 161**
- Antigenic drift and shift, 162
- Protection by serum antibody, 162
- Local factors, 162
- Cell-mediated immunity gets to the intracellular virus, 163
- Immunity to parasitic infections, 164**
- The host responses, 165
 - Humoral immunity, 165
 - Cell-mediated immunity, 166
- Evasive strategies by the parasite, 167
 - Resistance to effector mechanisms, 167
 - Avoiding antigen recognition by the host, 167
 - Deviation of the host immune response, 169
- Immunopathology, 169
- Summary, 169**
- Further reading, 171

viii

11 · IMMUNITY TO INFECTION

II — Prophylaxis and Immunodeficiency

- Passively acquired immunity, 172**
- Homologous antibodies, 172
 - Maternal, 172
 - γ -Globulin, 172
- Heterologous antibodies, 173
- Vaccination, 173**
- Killed organisms as vaccines, 173
- Live attenuated organisms have many advantages as vaccines, 174
 - Classical methods of attenuation, 174
 - Attenuation by recombinant DNA technology, 175
 - Constraints on the use of attenuated vaccines, 175
- Vaccines containing individual protective antigens, 177
 - The use of purified components, 177
 - Antigens can be synthesized through gene cloning, 177
 - Antigens can be mimicked by synthetic peptides, 178
 - Idiotypes can be exploited for vaccines, 178
- Adjuvants, 180
 - Depot effects, 181
 - Macrophage activation, 181
 - Specific effects on lymphocytes, 182
 - Anti-tumour action, 182
- New vehicles for antigen delivery, 182
- Primary immunodeficiency states in the human, 182**
- Deficiencies of innate immune mechanisms, 183
 - Phagocytic cell defects, 183
 - Complement system deficiencies, 183
- B-cell deficiency, 184
- T-cell deficiency, 185
- Stem-cell deficiency, 186

- Recognition of immunodeficiencies, 186
- Secondary immunodeficiency, 186**
- Acquired immunodeficiency syndrome (AIDS), 187
 - AIDS results from infection by a human immunodeficiency virus (HIV), 188
 - The AIDS infection depletes helper-T-cells, 188
 - Diagnosis of AIDS, 190
 - The control of AIDS, 191
- Summary, 191**
- Further reading, 192

12 · HYPERSENSITIVITY

- An inappropriate immune response can lead to tissue damage, 193
- Type I — anaphylactic hypersensitivity, 193**
- The phenomenon of anaphylaxis, 193
- Cross-linking of IgE receptors triggers mast cells, 194
- Atopic allergy, 195
 - Clinical tests for allergy, 196
 - Therapy, 197
- Type II — antibody-dependent cytotoxic hypersensitivity, 200**
- Type II reactions between members of the same species (isoimmune), 201
 - Transfusion reactions, 201
 - Rhesus incompatibility, 201
 - Organ transplants, 202
- Autoimmune type II hypersensitivity reactions, 203
- Type II drug reactions, 203
- Type III — immune-complex-mediated hypersensitivity, 203**
- Inflammatory lesions due to locally formed complexes, 205
 - The Arthus reaction, 205
 - Reactions to inhaled antigens, 205
 - Reactions to internal antigens, 207
- Disease resulting from circulating complexes, 207
 - Serum sickness, 207
 - Immune complex glomerulonephritis, 207
 - Deposition of complexes at other sites, 208
- Detection of immune complex formation, 209
- Treatment, 209
- Type IV — cell-mediated (delayed-type) hypersensitivity, 209**
- The cellular basis of type IV hypersensitivity, 210
- Tissue damage produced by type IV reactions, 210
 - Infections, 210
 - Contact dermatitis, 211
 - Other examples, 211
- Type V — stimulatory hypersensitivity, 211**
- 'Innate' hypersensitivity reactions, 212**
- Summary, 212**
- Further reading, 214

13 · TRANSPLANTATION

- Graft rejection, 215**
- Evidence that rejection is immunological, 215
- Genetic control of transplantation antigens, 216
- Some other consequences of H-2 incompatibility, 217

- Class II MHC differences produce a mixed lymphocyte reaction (MLR), 217
- Cell-mediated lympholysis (CML), 217
- The graft-vs-host reaction (g.v.h.), 217
- Mechanisms of graft rejection, 218
 - Lymphocyte-mediated rejection, 218
 - The role of humoral antibody, 218
- The prevention of graft rejection, 220**
- Matching tissue types on graft donor and recipient, 220
 - Methods for tissue typing, 221
 - The polymorphism of the human HLA system, 222
 - The value of matching tissue types, 223
- Agents producing general immunosuppression, 223
 - Lymphoid cell ablation, 224
 - Total lymphoid irradiation (TLI), 224
 - Immunosuppressive drugs, 224
- Strategies for antigen-specific depression of allograft reactivity, 225
- Clinical experience in grafting, 226**
- Privileged sites, 226
- Kidney grafts, 227
- Heart transplants, 227
- Liver transplants, 228
- Bone marrow grafting, 228
- Other organs, 229
- Association of HLA type with disease, 229**
- The immunological relationship of mother and fetus, 230**
- Is the cancer cell like an allograft?, 231**
- Changes on the surface of tumour cells, 231
- Immune response to tumours, 232
- Approaches to cancer immunotherapy, 233
 - Exploitation of acquired immune responses, 233
 - Harnessing innate immunity, 234
- Immunodiagnosis, 236
- Summary, 236**
- Further reading, 237

14 · AUTOIMMUNE DISEASES I — Scope and Aetiology

- The spectrum of autoimmune diseases, 238
- Autoantibodies in human disease, 239

- Overlap of autoimmune disorders, 239
- Genetic factors in autoimmune disease, 241
- Aetiology of autoimmune responses, 245
- T-inducer bypass mechanisms leading to autoimmunity, 246
 - Provision of new carrier determinant, 246
 - Idiotypic bypass mechanisms, 248
- Autoimmunity arising through bypass of regulatory mechanisms, 250
 - Suppressor circuits may not work, 250
 - Inappropriate expression of class II molecules, 252
- Summary, 253**

15 · AUTOIMMUNE DISEASES II — Pathogenesis, Diagnosis and Treatment

- Pathogenic mechanisms in autoimmune disease, 254**
- Effects of humoral antibody, 254
 - Blood, 254
 - Thyroid, 254
 - Intrinsic factor, 256
 - Sperm, 257
 - Glomerular basement membrane (gbm), 257
 - Muscle, 257
- Effects of complexes, 258
 - Systemic lupus erythematosus (SLE), 258
 - Rheumatoid arthritis, 258
- Cellular hypersensitivity, 264
- Experimental models of autoimmune disease, 266
 - Experimental autoallergic disease, 266
 - Spontaneous autoimmune disease, 268
- Diagnostic value of autoantibody tests, 268**
- Treatment of autoimmune disorders, 268**
- Metabolic control, 268
- Anti-inflammatory drugs, 269
- Immunosuppressive drugs, 270
- Immunological control strategies, 270
- Summary, 272**
- Further reading, 273

Index, 275

ix